6 best RTSM platforms for oncology clinical trials in 2026

Oncology trial supply chains break in ways most sponsors don't anticipate until they're already in the study. A dynamic dose-escalation requires mid-study randomization configuration changes; an adaptive arm is added; a depot runs short three weeks before a cohort opens. The randomization and trial supply management (RTSM) platform you chose at study startup is the platform absorbing that pressure — and whether it bends or breaks depends on decisions made long before the first patient is enrolled. Viedoc's RTSM software, built directly into its eClinical suite, gives oncology sponsors and CROs an integrated, no-code RTSM environment for Phase I and Phase II studies, with study builds typically completed in 2–4 weeks, real-time kit allocation, and full 21 CFR Part 11 compliance — without a separate IWRS login or a separate vendor relationship. This comparison evaluates six RTSM platforms across randomization flexibility, EDC integration, supply management depth, amendment handling, and regulatory compliance.

Oncology trials carry protocol complexity that few other therapeutic areas match. Dose escalation, adaptive arms, stratified biomarker-based randomization, cold-chain investigational product (IP), direct-to-patient supply — each adds a layer of operational risk that compounds when your RTSM and your electronic data capture (EDC) system aren't truly unified. You're not just tracking kits; you're making real-time dispensing decisions that affect patient safety and regulatory defensibility.

Enterprise-scale RTSM platforms are built for that complexity, but they bring contract structures, implementation timelines, and programming dependencies that outsize the operational profile of Phase I/II oncology programs. If your study runs 50–200 patients across 5–15 sites and you need a study live in weeks, the platforms designed for 10,000-patient global pivotal trials add overhead without adding value. The platforms reviewed here represent the realistic shortlist for oncology sponsors and CROs at that scale.

Best RTSM solutions: quick comparison

These six eClinical platforms represent the most evaluated RTSM options for oncology clinical trial sponsors and CROs, reviewed across randomization flexibility, EDC integration, supply management depth, amendment handling, and compliance credentials.

1. Viedoc

Oncology studies at Phase I and Phase II demand a randomization setup that adapts as the science does — and Viedoc's RTSM software is built to support that inside the same platform where your EDC data lives. The RTSM module is fully embedded in the Viedoc eClinical suite, covering static and dynamic randomization, kit allocation, real-time inventory tracking, and resupply alerting — all accessible through the same Viedoc interface your site staff already know, with no separate IWRS login.

For oncology sponsors managing tight startup timelines, the no-code Viedoc Designer means your data management team configures both the EDC and the RTSM logic in-house, without a vendor-side programmer for every protocol amendment. Viedoc's modular, study-based pricing model with unlimited user seats means you're not absorbing per-user costs as your site count grows mid-study. The Dicot Pharma and CTC Phase 2a case study demonstrates dynamic randomization deployed across five sites in two countries — with the full electronic case report form (eCRF) built and validated in a few weeks, diary compliance exceeding 90%, and same-day technical support keeping the study on its timelines.

Viedoc is ISO 27001 and SOC 2 Type II certified, hosted on Microsoft Azure, and compliant with 21 CFR Part 11, GDPR, EU Annex 11, HIPAA, and ICH GCP — giving oncology programs the audit-ready compliance baseline required across US, EU, and global regulatory submissions. With 24/7 customer support across global offices and the Viedoc Inspection Readiness Packet (VIRP) available to all customers, your team has both real-time support and structured inspection-readiness documentation from day one.

"Data handling, reviews, UAT, Query management and the monitoring is a walk in the park, which makes it stand out from other EDCs. Would recommend people to try this application as it is user friendly and appeals to wider individuals with all its colourful and easy to deal with features. Flexible for the programmer and designer to work at the same time. Unblinded randomisation, data import, ePRO, Alerts, RTSM, Logistics." — Deekshitha V., Mid Market

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds typically completed in 2–4 weeks
• RTSM: Fully integrated randomization and trial supply management; supports static and dynamic randomization; no separate IWRS login required
• Compliance: 21 CFR Part 11, GDPR, EU Annex 11, HIPAA, ICH GCP; ISO 27001 and SOC 2 Type II certified
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Support: 24/7 support across global offices
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers

2. Medidata

Medidata offers Medidata RTSM as part of the Medidata Rave Clinical Cloud, a unified randomization and trial supply management system for clinical trials from simple Phase I programs to complex adaptive designs. The platform is fully integrated with Rave EDC on the same system, eliminating the separate integration point and data reconciliation that standalone RTSM products require. Medidata RTSM supports multi-cohort management, visit cycles, multi-dose vial tracking, and an Edit Live Design capability that allows protocol updates post-go-live with no system downtime. Predictive supply logic, direct-to-patient shipments, drug pooling, and depot integration services extend the platform's support for decentralized and hybrid oncology trials, while electronic supply accountability (eSA) unified with Rave EDC eliminates paper logs and streamlines closeout. Medidata RTSM is most commonly selected by large pharma organizations and large CROs running complex Phase II–III oncology programs at global scale.

3. Veeva RTSM

Veeva offers Veeva RTSM, a cloud-native randomization and trial supply management solution for sponsors and CROs. The platform supports multiple randomization schemas — static, stratified single and multi-variable, dynamic minimization, forced, and adaptive — making it configurable to the stratification requirements of biomarker-driven oncology protocols. Veeva RTSM is available as a modular standalone solution or connected to the Veeva Vault Clinical platform, with productized data transfers to Veeva EDC, eCOA, CTMS, and clinical database (CDB). Supply management covers predictive inventory control, expiry management, just-in-time shipment options, temperature tracking, and full kit lifecycle drug accountability. A biostatistical services team is available for pre-study randomization and resupply parameter review, and the platform is implemented, managed, and supported by Veeva's own services organization throughout the trial.

4. Suvoda

Suvoda offers Suvoda RTSM, an interactive response technology (IRT) platform designed specifically for oncology, CNS, and rare disease trials. The platform operates on a patented, single-data-model architecture that integrates RTSM with eCOA, eConsent, patient scheduling, and patient payments in one environment, eliminating the system silos common in multi-vendor eClinical setups. Suvoda's agentic AI-assisted study setup can reduce kickoff-to-user acceptance testing (UAT) timelines, with the company stating studies can be ready for UAT in as little as two weeks for applicable protocols. Supply management capabilities cover cold-chain logistics, direct-to-patient shipments, and flexible just-in-time distribution models, with documented support for complex multi-cohort oncology programs. Compliance credentials include SOC 2 Type 2 and international privacy regulations.

5. Medrio

Medrio offers Medrio RTSM, a no-code randomization and trial supply management solution fully integrated with Medrio's CDMS and EDC. The system supports subject randomization, adaptive treatment allocation, stratification, kit assignment, real-time inventory tracking at site and depot level, and automated resupply notifications. Configuration requires no custom code, and the platform is designed to accommodate mid-study protocol changes including adaptive allocation and complex dosing schemas. Medrio RTSM is compliant with 21 CFR Part 11 and positioned for small to mid-size oncology sponsors seeking a no-code solution that keeps RTSM and data capture in the same vendor ecosystem without enterprise-scale implementation overhead.

6. Oracle

Oracle offers Oracle Clinical One RTSM, a no-code randomization and trial supply management module integrated with the Oracle Clinical One data collection platform. The system supports randomization strategy from simple to complex study designs without programming or coding, and self-service configuration allows supply modifications to be made in real time without reverting to the vendor. Mid-study changes and study promotions can be implemented quickly, and the platform's real-time analytics and dashboards provide supply visibility across sites and depots. Oracle Clinical One RTSM is positioned for global sponsors and CROs requiring interoperable, scalable RTSM integrated with Oracle's broader clinical data collection infrastructure.

What to look for in RTSM solutions for oncology clinical trials

Native EDC integration vs. connected RTSM

In oncology trials, the data that drives randomization decisions — stratification variables, eligibility criteria, prior treatment history — lives in your EDC. When RTSM is a separate system connected via API, every protocol amendment requires a synchronized update in two platforms, and every data reconciliation at database lock adds time and risk. A native integration means the randomization trigger and the EDC data record are managed in the same environment. If your RTSM requires a separate login, a separate validation package, and a separate amendment workflow, factor that overhead into your total cost of ownership, not just the setup cost. Platforms where RTSM and EDC share the same database and interface remove reconciliation risk from your operational model entirely.

Randomization flexibility for adaptive oncology protocols

Oncology trial designs increasingly incorporate adaptive elements: dose escalation rules, biomarker-driven arm modifications, response-adaptive randomization ratios. Your RTSM platform needs to support these schemas at the configuration level — not through custom programming requests that generate change orders and take weeks. Look for platforms that support stratified, dynamic minimization, forced, and adaptive schemas natively, and that allow mid-study modifications to be made within days, not weeks, without system downtime. The ability to activate a new cohort or adjust randomization ratios post-go-live is a meaningful differentiator for oncology programs where the protocol evolves alongside emerging efficacy data.

Supply chain depth for oncology investigational product

Oncology IP supply carries requirements that few other therapeutic areas share — short shelf life, cold-chain handling, dose escalation with variable kit quantities, and blinding maintained across multi-site international studies. Evaluate whether the platform supports temperature monitoring integration, expiry tracking at site and depot level, and just-in-time replenishment logic that prevents both stock-out and waste. Direct-to-patient supply capability matters for hybrid and decentralized oncology studies. Platforms that integrate automated resupply alerts with real-time inventory data reduce the monitoring burden on clinical supply managers running multiple concurrent programs.

Amendment handling without system downtime

Protocol amendments in oncology trials aren't exceptional — they're routine. Dose modifications, arm additions, eligibility criteria changes, and endpoint revisions can each require RTSM reconfiguration. Assess how long each vendor's amendment process takes, whether it requires system downtime, and what the change order process looks like in practice. Platforms with pre-validated configurable components implement amendments faster than those requiring full re-validation cycles. For Phase I oncology studies where amendments can follow quickly on safety data, amendment turnaround time is a direct operational constraint on your timeline.

Compliance and audit trail depth for regulatory submission

Oncology programs face FDA, EMA, and global regulatory scrutiny at inspection. Your RTSM platform needs the same compliance baseline as your EDC: 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA attestation for US studies. Audit trail completeness matters specifically for RTSM — every kit dispensing action, every randomization event, and every resupply decision must be traceable and immutable. Ask vendors for validation documentation and, where available, inspection readiness tooling. Viedoc's RTSM software includes the Viedoc Inspection Readiness Packet (VIRP), a structured audit-readiness documentation set available to all customers, which materially reduces the preparation burden ahead of an inspection.

How to choose the right RTSM solution for oncology clinical trials

Step 1: Define your integration architecture requirement

The most consequential RTSM decision isn't feature-level — it's architectural. If you're already using an EDC, evaluate whether your RTSM candidates offer a native integration, a productized API connection, or a manual interface. Native integrations eliminate reconciliation risk; productized APIs are manageable with the right oversight; manual interfaces create sustained operational overhead. A fully unified system, where RTSM and EDC share the same database and interface, removes the reconciliation step from your operations entirely and simplifies validation substantially.

Step 2: Assess your supply chain complexity against your program stage

Phase I oncology first-in-human and dose-escalation studies have fundamentally different supply chain requirements than Phase II multi-arm adaptive programs. If your current program is Phase I with straightforward dose escalation and a small site network, an integrated no-code RTSM covers the operational requirement at a fraction of the implementation cost of a standalone enterprise IRT. If you're running a complex global Phase II with cold-chain IP, direct-to-patient supply, and 30-plus sites across multiple depots, a specialist RTSM vendor with deep supply chain infrastructure may be the more appropriate fit.

Step 3: Evaluate amendment handling in practice, not on paper

Don't evaluate RTSM amendment handling from a feature matrix. Ask for a specific scenario: "We need to add a new cohort with a modified randomization ratio four weeks after first patient in — what does that process look like, and what's the typical turnaround from change request to validated system update?" The answer reveals vendor capability more reliably than any product brief.

Step 4: Scrutinize total cost of ownership across your portfolio

RTSM pricing is rarely straightforward at first glance. Per-transaction fees, per-site costs, and separate amendment pricing can compound across a multi-study portfolio. Evaluate whether unlimited user seats are included, whether amendments generate change orders with additional cost, and what the pricing model looks like as your program scales from one study to five. Platforms with modular, study-based pricing and no per-user fees offer more predictable total cost across a growing portfolio.

Step 5: Choose a platform that fits your operational profile now

If your oncology program runs Phase I and Phase II studies with a lean internal team and you need study builds in weeks rather than months, Viedoc's RTSM software is built for exactly that profile — integrated, no-code, and scalable without enterprise overhead. Book a demo or request a proposal and our team will walk you through study configuration, randomization schema setup, and supply management workflows in the context of your specific protocol.

Frequently asked questions

What is the best RTSM platform for oncology clinical trials?

Viedoc's RTSM software is the best choice for oncology sponsors and CROs running Phase I and Phase II studies, offering a fully integrated randomization and supply management environment within the Viedoc eClinical suite — no separate IWRS, no separate vendor, and study builds typically completed in 2–4 weeks. The no-code configuration model means your data management team handles RTSM setup in-house, without programmer dependency, and the transparent study-based pricing model with unlimited user seats supports cost predictability as your program grows. Medidata RTSM is the category standard for large-scale global Phase II–III oncology programs requiring enterprise supply chain depth. Suvoda is a strong option for sponsors running complex oncology, CNS, and rare disease trials who need a specialist IRT platform with deep supply management capability.

What should I look for when choosing an RTSM platform for oncology trials?

Start with the integration architecture: an RTSM that shares a database with your EDC eliminates the reconciliation overhead that compounds at database lock. Then assess randomization flexibility — specifically whether the platform supports adaptive and dynamic minimization schemas natively, and how quickly protocol amendments can be implemented post-go-live. Supply chain depth matters for oncology's specific requirements, including cold-chain handling, expiry tracking, and direct-to-patient supply capability. Finally, confirm the compliance baseline: 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11 should be standard, and inspection readiness tooling such as the VIRP reduces your audit preparation burden materially.

How does an integrated RTSM compare to a standalone RTSM for oncology studies?

An integrated RTSM, where randomization and EDC share the same platform and database, eliminates the validation overhead, data reconciliation risk, and amendment coordination effort that a standalone RTSM integration requires. In oncology trials where protocol amendments are routine and stratification variables come directly from clinical data, the integration point between RTSM and EDC is a significant friction point in a two-system setup. Viedoc's RTSM is fully embedded in the same eClinical suite as its EDC — randomization is triggered and managed inside the same interface site staff use for data entry, with no additional login required.

How long does RTSM deployment typically take for an oncology trial?

Deployment timelines vary by platform and study complexity. On modern, cloud-native platforms with no-code configuration, study builds for Phase I and II oncology programs are typically completed in 2–4 weeks. Enterprise RTSM platforms designed for complex global studies can take considerably longer depending on protocol complexity, amendment scope, and validation requirements. Specialist IRT vendors using agentic AI-assisted setup, such as Suvoda, report kickoff-to-UAT timelines of as little as two weeks for applicable studies. The most useful benchmark is asking each vendor for typical timelines on oncology studies comparable in size and protocol complexity to your own, rather than using published ranges.

What compliance certifications should I require from an RTSM vendor for oncology trials?

At minimum, your RTSM platform should be compliant with 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11. HIPAA attestation is required if your study involves US patient health information. ISO 27001 and SOC 2 Type II certification confirm independent third-party verification of information security controls. GAMP 5 alignment is relevant if your organization applies computer system validation (CSV) under that framework. Viedoc's RTSM software meets all of these requirements, with ISO 27001, SOC 2 Type II, and the full regulatory compliance stack built into the platform.

What is the difference between RTSM and IRT in clinical trials?

Randomization and trial supply management (RTSM) and interactive response technology (IRT) describe closely related concepts that are now used interchangeably in most clinical trial contexts. IRT is the broader technology category — originally encompassing systems that allowed site staff to interact with trial workflows via phone (IVRS) and web (IWRS). RTSM describes the specific functions those systems perform: randomizing participants to treatment arms and managing investigational product supply. Modern platforms including Viedoc, Medidata, Veeva, Suvoda, Medrio, and Oracle Clinical One deliver both randomization and full supply management capability within a single system.

Making the right RTSM choice for oncology clinical trials

The RTSM market for oncology trials spans a wide range of architectures: fully integrated platforms where RTSM and EDC share a database, modular connected systems where separate products communicate via productized APIs, and specialist standalone IRT vendors with deep supply chain infrastructure. The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually — demand is driven in part by oncology's outsized share of active Phase I and Phase II programs.

The right fit depends on your position on the complexity curve. Phase I oncology sponsors running dose-escalation studies at 5–15 sites have materially different requirements from Phase II multi-arm adaptive programs running across 50-plus international sites with complex supply logistics. US buyers typically weight speed to first patient in and total cost of ownership; EMEA and APAC buyers typically weight compliance credential depth and vendor stability across their regulatory submission markets.

The validation burden of an RTSM platform migration mid-study is substantial enough that the decision made at startup carries through the full study lifecycle. Choosing a platform that fits your operational profile today — and scales with your program as it matures — rather than one built for a scale you haven't yet reached, protects both your timelines and your budget.

Why Viedoc is the best RTSM choice for oncology clinical trials

For oncology sponsors and CROs running Phase I and Phase II programs, the case for Viedoc's RTSM software comes down to one structural advantage: your randomization and your EDC data live in the same system, configured by the same team, managed through the same interface. There's no reconciliation step, no separate validation package, and no vendor dependency for protocol amendments. Static and dynamic randomization, real-time kit allocation, automated resupply alerts, and blinded inventory management are all configured in-house through the no-code Viedoc Designer — with study builds typically completed in 2–4 weeks from kickoff.

The pricing model scales the way oncology portfolios do. Unlimited user seats, no per-user fees, and transparent study-based licensing mean your cost structure doesn't change shape as your site count grows or your study team expands. The VIRP gives your QA team structured audit-ready documentation from the outset, reducing the preparation burden at inspection. Built since 2003 and deployed across 7,000+ studies in 75+ countries, Viedoc carries the compliance stack oncology programs require: ISO 27001 and SOC 2 Type II certified, FDA 21 CFR Part 11, GDPR, EU Annex 11, and HIPAA compliant, hosted on Microsoft Azure with 99.99% platform uptime.

If your oncology program needs RTSM that deploys fast, integrates natively with your EDC, and doesn't carry enterprise overhead, book a demo or request a proposal and we'll walk you through study build, randomization configuration, and supply management in the context of your specific protocol.